Oncology Business Management | Specialty

Brand-name Oral Oncologics Drive Spending Trend, Study Says

October 7th 2014

Spending on 47 currently available oral oncologic drugs has increased from $940 million in the first quarter of 2006 to $1.4 billion in the third quarter of 2011, according to results of a study by Rena M. Conti, PhD, and colleagues at the University of Chicago.

Commercial Tests Offer Guidance in Bladder, Renal, Testicular Cancers

October 7th 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

How Oncologists Stay Current in Today's Medical Landscape

October 6th 2014

In 2014, the amount of medical and other information has only increased, and mobile devices such as smartphones and tablets make it even easier to access that data.

Is Breast Cancer Vaccination Coming?

October 1st 2014

Dr. Patrick Borgen Talks About Advances in Breast Cancer

October 1st 2014

Dr. Patrick Borgen Discusses the "Jolie Effect"

October 1st 2014

Dr. Patrick Borgen on the Future of Breast Cancer Treatment

October 1st 2014

The Ongoing Debate Over Mammography-Screening Matters

October 1st 2014

Prophylactic Double Mastectomy-Does it Make a Difference?

October 1st 2014

ATEMPT Trial at Dana-Farber Cancer Institute

October 1st 2014

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

Physician Providers Still Lagging in ICD-10 Readiness

September 26th 2014

Although the ICD-10 launch was moved to October 1, 2015, vendors and health plans look to be making some progress on the switchover. The same can't be said for physician providers, however.

Practices in Bundled Payment Program Credit Medical Home Structure for Success

September 26th 2014

In July, UnitedHealthcare (UHC) reported that an innovative program using bundled payment for cancer care resulted in an impressive 34% reduction in medical costs when compared with costs for a control group

Amgen Seeks FDA Approval for Blinatumomab in ALL

September 22nd 2014

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Dr. Lazarus Discusses Companion Diagnostics

September 18th 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

When Science Outpaces Payers: Molecular Diagnostics Pose Reimbursement Dilemmas

September 17th 2014

As precision medicine continues to evolve in cancer care, the development of highly sophisticated tests that leverage the explosion of knowledge about the molecular and protein characteristics of an individual patient's tumor has emerged as its own scientific frontier.

Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer

September 16th 2014

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Differences Identified Between What Medicare Covers and What Patients with Cancer Want

September 15th 2014

Does Medicare coverage for patients with cancer match up to what they actually want covered? There appears to be a mismatch between covered benefits and beneficiary preferences that involves quality of life and financial burden of care, according to a study from Duke University.

Urologists Discuss Their Use of Biomarker Tests in Considering Active Surveillance

September 12th 2014

Experts Touch On Oncotype DX, Other Assays During Peer Exchange